Editorial Mode: CLARUS_ANALYSIS Index Recommendation: INDEX Language/Role: FULL_ANALYSIS Fact-Check Date: 2024
Executive Summary
The Federal Council and Parliament are increasing the minimum deductible in health insurance from 300 to 400 Swiss francs. This measure aims to encourage insured persons to visit doctors less frequently and is expected to save approximately 280 million Swiss francs. The primary victims are sick and poor people who cannot afford higher out-of-pocket costs. In parallel, Parliament rejected several alternative cost-saving measures that would have generated higher savings, but would burden doctors, hospitals, and the pharmaceutical industry.
Key Figures
- Michele Genoni (President of the professional organization of surgeons)
- Federal Councillor Baume-Schneider (responsible for health policy)
Topics
- Healthcare costs and cost containment
- Health insurance and deductibles
- Lobbying and conflicts of interest
- Generic drug markets and medication prices
- Patient access to medical care
Clarus Lead
The franchise increase reveals a structural problem in Swiss health policy: While cost-saving measures that affect patients and vulnerable groups are being implemented, more expensive reform proposals systematically fail due to parliamentary veto—not for substantive reasons, but due to vested interests. Parliament rejected savings ideas with potential savings of up to 500 million Swiss francs because they would burden medical service providers. This asymmetry in interest representation—strong lobbies of doctors and pharma versus the absent voice of premium payers—shapes political capacity to act.
Detailed Summary
The reference pricing system for generic drugs would have saved an estimated up to 500 million Swiss francs by allowing health insurance companies to pay only a maximum amount for patented-protected medications. Parliament rejected it—citing supply security and therapeutic freedom as reasons. Result: Swiss generic drugs cost double compared to neighboring countries.
A second failed proposal was a coordination system for doctors, hospitals, and therapists, with estimated 250 million Swiss francs in cost-saving potential. The argument against it: too much bureaucracy, although coordination already occurs via primary care doctor models.
The roundtable on cost containment with all stakeholders—cantons, medical professionals, hospitals, insurers, pharma—developed 38 measures with only 300 million Swiss francs in savings. For comparison: Basic insurance paid out 2.3 billion Swiss francs more in 2024 than in 2023.
A Federal Office study from 2020 showed the actual cost-saving potential: 8.4 billion Swiss francs (19 percent of total costs) could be saved without patient harm—by eliminating unnecessary treatments and reducing inflated medication and implant prices. Hardly any of this has been implemented. Premiums have risen by 25 percent since then.
Surgeon Michele Genoni publicly confirmed the lobbying practice: "We have contacted parliamentarians. We try to influence Federal Councillor Baume-Schneider and the EDI." By contrast, the representation of premium and taxpayers receives hardly any hearing in Parliament.
Key Statements
- The franchise increase disproportionately burdens sick and poor insured persons, while more effective cost-saving measures fail due to lobbying.
- Parliament rejected three alternative savings proposals (500 + 250 + 300 million Swiss francs), which would, however, burden doctors, hospitals, or pharma.
- A Federal Office study identified 8.4 billion Swiss francs in cost-saving potential without patient harm—not yet implemented.
- Strong lobbies of service providers have direct access to Parliament and government; premium payers are unorganized.
Critical Questions
Evidence/Data Quality: Is the assumption that the franchise increase will lead to fewer doctor visits based on empirical data from comparable cantons or countries, or is it purely a theoretical expectation?
Conflicts of Interest: To what extent have lobbies (namely the medical profession and pharma) directly influenced parliamentary committees or federal councilors in rejecting the reference pricing system—can these contacts be documented?
Causality/Alternatives: Is it established that the 2.3 billion in additional spending in 2024 is primarily due to inefficient treatments or price inflation, or do demographics and medical technology innovation also play a role?
Feasibility/Side Effects: What are the consequences of the franchise increase for preventive care participation and early detection among low-income earners—is there a risk of an increase in later, more expensive treatments?
Source Validity: The 8.4-billion study from the BAG dates from 2020—are these scenarios still realistic assumptions given cost developments 2021–2024?
Conflicts of Interest (Media): How independent is Beobachter's criticism, given its own petition for "participation"—could this be interpreted as editorial campaign work?
Sources
Primary Source: Politics saves on the backs of the elderly and sick – Beobachter.ch https://www.beobachter.ch/gesundheit/die-politik-spart-auf-dem-buckel-der-alteren-und-kranken-920831
Supplementary Sources (cited in article):
- Federal Council matter: Increase in minimum deductible
- International price comparison: Medication prices
- Roundtable on cost containment: 38 measures
- Interview Michele Genoni: Surgeon lobbying work
- Federal Office of Public Health (2020): Cost-containment potential (8.4 billion CHF)
Verification Status: ✓ 2024
This text was created with the support of an AI model. Editorial responsibility: clarus.news | Fact-checking: 2024
Note on User Supplementary Question
Does the measure effectively contribute to cost containment or is it factually a premium exaltation?
Answer from Article Content: The article implicitly makes clear that the franchise increase represents a cost shift rather than cost containment. The expected 280 million Swiss francs in savings are marginal compared to the 2.3 billion in additional spending in 2024. It acts as a regressive redistribution measure: Rather than reducing system costs, it reduces utilization by poorer patients (quantity discount effect). The BAG study shows that genuine cost reduction (8.4 billion CHF) would be possible—through price negotiation and efficiency gains, not through shifting costs to patients.